News

Research and ongoing clinical trials are giving some hope to those with ichthyosis but for now most people manage their disease symptomatically.

In this week’s Pointers With Portela, the 208SkinDoc reviews questions from social media about micro-needling, retinol, and sunscreen use.

In rare cases, chromhidrosis may be associated with underlying medical conditions, such as hyperthyroidism, dermatitis herpetiformis, and multiple myeloma.

The 3-year project aims to set national standards for using new levels of computer learning in health care.

This week's edition of the Mainstream Patient features stories about barrier repair products for dry skin, face mapping for acne, how to reapply sunscreen over makeup, and more.

With the social media boom, skin care advice is readily available. Unfortunately, some of the information on TikTok is harmful.

In part 3 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

Ritlecitinib is the first and only treatment cleared for adolescents with severe alopecia areata.

A new resource to share with patients follows Nina, who shares the mental and emotional toll of psoriasis and how she manages the condition.

If you weren’t able to attend the 2023 Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference or want to review our latest coverage and interviews, our full recap has you covered.

Click here to answer today's poll.

Catch up on coverage from the fourth and final day of the 2023 SDPA Annual Summer Dermatology Conference.

Want to reminisce on your time on Boston? View our conference photo gallery below.

As SDPA summer sessions have concluded, Arash Mostaghimi, MD, MPA, MPH, delves into what lies ahead in the dermatology industry—including the importance of collaboration between physicians and PAs.

Orit Markowitz, MD, discusses the future of non-invasive lasers in removing skin cancer and cancerous lesions, ultimately allowing patients to leave the practice without a bandaid.

Jane Mast, PhD, DMSc, MPAS, discusses empathetic care in hidradenitis suppurativa and the importance of supporting patients with HS in every step of their journey with the condition.

Arash Mostaghimi, MD, MPA, MPH, provides a comprehensive overview of his SDPA conference sessions, "Understanding the Pathology Report and Basic Biopsies," "Beyond the H&E," and "Alopecia: Treating Challenging Cases."

The drug also demonstrated efficacy in improving sleep quality and reducing sleep disruption.

In recognition of World Vitiligo Day, the Dermatology Times team is spotlighting advances and educational opportunities for the condition.

Melodie Young, MSN, ANP-c, shares pearls on why prioritizing skin checks during Psoriasis Action Month in August is critical.

Catch up on coverage from the third day of the 2023 SDPA Annual Summer Dermatology Conference.

Ahmad Amin, MD, FAAD, reviews biologic selection in patients with psoriatic disease.

Megan Noe, MD, MPH, MSCE, reviews best practices for treating patients with cutaneous blisters and managing chronic bullous disorders.

Joslyn Kirby, MD, discusses the importance of awareness and recognition in hidradenitis suppurativa from a clinician and patient perspective.

A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.

With bimekizumab, the conservative imputation method led to higher response rates, achieved endpoints, and blocked IL-17A and IL-17F.

The National Psoriasis Foundation found that patients were frustrated by a lack of treatment options.

In a Maui Derm NP+PA Summer poster presentation, investigators revealed that treatment with spesolimab resulted in a reduction of lesions.

Catch up on coverage from the second day of the 2023 SDPA Annual Summer Dermatology Conference.

Over 24 weeks, dupilumab demonstrated efficacy in patients with chronic spontaneous urticaria.